富瑞研究报告指,康方生物(09926.HK) 日前公布,与合作伙伴Summit Therapeutics(SMMT.US) 合作的HARMONi全球试验,证明中国的数据可转化至全球,对于所有中国生物科技公司的对外授权都至关重要。虽然市场忧虑对于整体生存期(OS)的监管会更为严格,但该行并不担心,因为中国以外的OS数据成熟度不到50%,Summit Therapeutics将根据进一步的OS数据...
Source Link富瑞研究报告指,康方生物(09926.HK) 日前公布,与合作伙伴Summit Therapeutics(SMMT.US) 合作的HARMONi全球试验,证明中国的数据可转化至全球,对于所有中国生物科技公司的对外授权都至关重要。虽然市场忧虑对于整体生存期(OS)的监管会更为严格,但该行并不担心,因为中国以外的OS数据成熟度不到50%,Summit Therapeutics将根据进一步的OS数据...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.